Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
종목 코드 THRD
회사 이름Third Harmonic Bio Inc
상장일Sep 15, 2022
CEO- -
직원 수53
유형Ordinary Share
회계 연도 종료Sep 15
주소1700 Montgomery Street
도시SAN FRANCISCO
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호94111
전화12097272457
웹사이트https://thirdharmonicbio.com/
종목 코드 THRD
상장일Sep 15, 2022
CEO- -
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음